Savaysa

Active Ingredient(s): Edoxaban
FDA Approved: * January 8, 2015
Pharm Company: * DAIICHI SANKYO
Category: Blood Thinner (Anticoagulant)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Savaysa Overview

Edoxaban (DU-176b, trade names Savaysa, Lixiana) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery.[1] It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.[2] Contents 1 Medical uses 2 Contraindicati...

Read more Savaysa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Edoxaban

Recent Savaysa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Edoxaban

Tablet: 15mg, 30mg, 60mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Savaysa: (3 results)

Sorted by National Drug Code

65597-201 Savaysa 15 mg Oral Tablet, Film Coated by Daiichi Sankyo, Inc.
65597-202 Savaysa 30 mg Oral Tablet, Film Coated by Daiichi Sankyo, Inc.
65597-203 Savaysa 60 mg Oral Tablet, Film Coated by Daiichi Sankyo, Inc.

Other drugs which contain Edoxaban or a similar ingredient: (1 result)

EDOXABAN